The Finnish trial of prostate cancer screening: where are we now?
Department of Clinical Chemistry, University of Helsinki, Helsinki, Finland. patrik.finne@hus.fi
P
P
Finne
U H
UH
Stenman
L
L
Määttänen
T
T
Mäkinen
T L J
TL
Tammela
P
P
Martikainen
M
M
Ruutu
M
M
Ala-Opas
J
J
Aro
P J
PJ
Karhunen
J
J
Lahtela
P
P
Rissanen
H
H
Juusela
M
M
Hakama
A
A
Auvinen
D000368:Aged; D001706:Biopsy / Q000379:methods; D003362:Cost-Benefit Analysis; D005387:Finland / Q000453:epidemiology; D006801:Humans; D008297:Male; D008403:Mass Screening / Q000379:methods*; D008875:Middle Aged; D010375:Pedigree; D011379:Prognosis; D011467:Prostate / Q000473:pathology*; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000401:mortality; D011788:Quality of Life
D017430:Prostate-Specific Antigen